Meghalaya Magazine

Dermatomyositis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Priovant Therapeutics Inc., Corbus Pharmaceuticals, CSL Behring

 Breaking News
  • No posts were found

Dermatomyositis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Priovant Therapeutics Inc., Corbus Pharmaceuticals, CSL Behring

March 10
07:13 2023
Dermatomyositis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Priovant Therapeutics Inc., Corbus Pharmaceuticals, CSL Behring
The Dermatomyositis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dermatomyositis pipeline products will significantly revolutionize the Dermatomyositis market dynamics.

DelveInsight’s “Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Dermatomyositis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Insights

 

Dermatomyositis Overview

Dermatomyositis is a type of inflammatory myopathy characterized by inflammatory and degenerative changes of the muscles and skin. Associated symptoms and physical findings may vary widely from case to case as patients may present differently. Muscle abnormalities may begin with aches and weakness of the muscles of the trunk, upper arms, hips, and thighs (proximal muscles).

 

Some of the key facts of the Dermatomyositis Market Report: 

  • The Dermatomyositis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per Waseem (2022), DM is more common in women than in men, with incidence rates being 3.98 and 4.68 per 1,000,000 respectively
  • As per Orphanet et al. (n.d.), the annual incidence of adult dermatomyositis is estimated between 1.9-7.7/1,000,000. The incidence of juvenile dermatomyositis (JDM) 1/250,000-500,000 children
  • Key Dermatomyositis Companies: Priovant Therapeutics Inc., Corbus Pharmaceuticals, CSL Behring, Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd., Cipla Inc., Dr Reddy’s Laboratories Ltd., Abbott, F. Hoffmann-La Roche Ltd., Pfizer Inc., Zydus Group, Lupin, Amorphex Therapeutics Holdings, Inc., Bausch Health Companies Inc., and others
  • Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, and others
  • The Dermatomyositis epidemiology based on gender analyzed that dermatomyositis is more common in women than in men (2:1)

 

Get a Free sample for the Dermatomyositis Market Report – 

https://www.delveinsight.com/sample-request/dermatomyositis-market

 

Key benefits of the Dermatomyositis Market report:

  1. Dermatomyositis market report covers a descriptive overview and comprehensive insight of the Dermatomyositis Epidemiology and Dermatomyositis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Dermatomyositis market report provides insights on the current and emerging therapies.
  3. Dermatomyositis market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Dermatomyositis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Dermatomyositis market.

 

Download the report to understand which factors are driving Dermatomyositis epidemiology trends @ Dermatomyositis Epidemiological Insights 

 

Dermatomyositis Market  

The dynamics of the Dermatomyositis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“Brepocitinib, Lenabasum, HIZENTRA, and other emerging therapies are giving positive topline results, in their clinical trials. These emerging therapies are in mid phase of its clinical trials and are awaiting a launch which will make the pipeline robust.”

 

Dermatomyositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Dermatomyositis Epidemiology Segmentation:

The Dermatomyositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Dermatomyositis
  • Prevalent Cases of Dermatomyositis by severity
  • Gender-specific Prevalence of Dermatomyositis
  • Diagnosed Cases of Episodic and Chronic Dermatomyositis

 

Dermatomyositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomyositis market or expected to get launched during the study period. The analysis covers Dermatomyositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomyositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Dermatomyositis market share @ Dermatomyositis market forecast 

 

Dermatomyositis Therapies and Key Companies

  • Brepocitinib: Priovant Therapeutics, Inc.
  • Lenabasum: Corbus Pharmaceuticals
  • HIZENTRA: CSL Behring

 

Scope of the Dermatomyositis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Dermatomyositis Companies: Priovant Therapeutics Inc., Corbus Pharmaceuticals, CSL Behring, Novartis AG, Endo International Inc, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd., Cipla Inc., Dr Reddy’s Laboratories Ltd., Abbott, F. Hoffmann-La Roche Ltd., Pfizer Inc., Zydus Group, Lupin, Amorphex Therapeutics Holdings, Inc., Bausch Health Companies Inc., and others
  • Key Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, and others
  • Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
  • Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Dermatomyositis Unmet Needs, KOL’s views, Analyst’s views, Dermatomyositis Market Access and Reimbursement 

 

Table of Contents 

1. Dermatomyositis Market Report Introduction

2. Executive Summary for Dermatomyositis

3. SWOT analysis of Dermatomyositis

4. Dermatomyositis Patient Share (%) Overview at a Glance

5. Dermatomyositis Market Overview at a Glance

6. Dermatomyositis Disease Background and Overview

7. Dermatomyositis Epidemiology and Patient Population

8. Country-Specific Patient Population of Dermatomyositis 

9. Dermatomyositis Current Treatment and Medical Practices

10. Dermatomyositis Unmet Needs

11. Dermatomyositis Emerging Therapies

12. Dermatomyositis Market Outlook

13. Country-Wise Dermatomyositis Market Analysis (2019–2032)

14. Dermatomyositis Market Access and Reimbursement of Therapies

15. Dermatomyositis Market Drivers

16. Dermatomyositis Market Barriers

17.  Dermatomyositis Appendix

18. Dermatomyositis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Dermatomyositis treatment, visit @ Dermatomyositis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services